贝达药业筹划发行H股并在香港联交所上市

Core Viewpoint - Beida Pharmaceutical plans to issue overseas listed shares (H-shares) and apply for listing on the Hong Kong Stock Exchange to enhance its capital strength and competitiveness while advancing its internationalization process [1] Group 1: Company Actions - The company aims to consider the interests of existing shareholders and the conditions of domestic and international capital markets during the issuance process [1] - The issuance and listing will be completed at an appropriate time and issuance window within the validity period of the shareholders' meeting resolution, which is 18 months from the approval date or any extended period agreed upon [1]